Home > Oncology > ASCO 2020 > Breast & Ovarian Cancer > BYLieve demonstrates efficacy of PIK3CA-directed treatment post CDK4/6-ihibition

BYLieve demonstrates efficacy of PIK3CA-directed treatment post CDK4/6-ihibition

Presented By
Prof. Hope S. Rugo, University of California San Francisco, CA, USA
Conference
ASCO 2020
Trial
Phase 2, BYLieve
The phase 2 BYLieve trial demonstrated that the combination of alpelisib and fulvestrant has a clinically meaningful efficacy in patients with PIK3CA-mutated hormone receptor (HR)-positive advanced breast cancer who progressed on treatment with CDK4/6 inhibitors plus an aromatase inhibitor, with manageable side effects. PIK3CA is one of the most frequently mutated genes in breast cancer and a negative prognostic factor in HR-positive, HER2-negative advanced breast cancer. Approximately 40% of patients with this disease have a mutation of the PIK3CA gene in their tumour [1]. Alpelisib – an alpha-selective PI3 kinase inhibitor – plus fulvestrant recently demonstrated efficacy in the phase 3 SOLAR-1 trial in patients with HR-positive PIK3CA-mutant advanced breast cancer progressing on an aromatase inhibitor, nearly doubling the median progression-free survival (PFS) from 5.7 months in the placebo arm to 11 months in the alp...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on